MLYS as reported
- Net Income
- −$350M
Net Income · +83% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- −$142M
Free Cash Flow · trailing twelve months to Q4 2025
- EPS
- −$4.19
EPS · +18% year on year · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Net Income | −$350M | +83% | Q2 2026 |
| EPS | −$4.19 | +18% | Q2 2026 |
| ROE | −35% | n/a | Q2 2026 |
| ROA | −32% | n/a | Q2 2026 |
| Free Cash Flow | −$142M | n/a | Q4 2025 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Mineralys Therapeutics, Inc. (MLYS) - Net IncomeNet IncomeMineralys Therapeutics, Inc. (MLYS)